Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

Open Label ◽

Phase 3 ◽

Faculty of 1000 evaluation for Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.718018463.793480272 ◽

2013 ◽

Author(s):

Sandra Nuyts

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Randomised Trial ◽

Open Label ◽

Phase 3 ◽

Pazopanib plus cetuximab in recurrent or metastatic head and neck squamous cell carcinoma: an open-label, phase 1b and expansion study

The Lancet Oncology ◽

10.1016/s1470-2045(18)30350-4 ◽

2018 ◽

Vol 19 (8) ◽

pp. 1082-1093 ◽

Cited By ~ 5

Author(s):

Douglas Adkins ◽

Paul Mehan ◽

Jessica Ley ◽

Marilyn J Siegel ◽

Barry A Siegel ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Open Label ◽

Open Label Phase ◽

Phase 1B

Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial

The Lancet Oncology ◽

10.1016/s1470-2045(13)70181-5 ◽

2013 ◽

Vol 14 (8) ◽

pp. 697-710 ◽

Cited By ~ 301

Author(s):

Jan B Vermorken ◽

Jan Stöhlmacher-Williams ◽

Irina Davidenko ◽

Lisa Licitra ◽

Eric Winquist ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Randomised Trial ◽

Open Label ◽

Phase 3 ◽

A Randomized, Open-Label, Phase II Study of Afatinib Versus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

Annals of Oncology ◽

10.1016/s0923-7534(20)32015-9 ◽

2012 ◽

Vol 23 ◽

pp. xi35 ◽

Cited By ~ 14

Author(s):

T.Y. Seiwert ◽

J. Fayette ◽

D. Cupissol ◽

J.M. DelCampo ◽

P.M. Clement ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Phase Ii ◽

Squamous Cell ◽

Phase Ii Study ◽

Open Label ◽

Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study

Annals of Oncology ◽

10.1016/j.annonc.2020.04.001 ◽

2020 ◽

Vol 31 (7) ◽

pp. 942-950 ◽

Cited By ~ 8

Author(s):

R.L. Ferris ◽

R. Haddad ◽

C. Even ◽

M. Tahara ◽

M. Dvorkin ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Phase Iii ◽

Open Label ◽

Open Label Phase ◽

Phase Iii Study

Faculty Opinions recommendation of Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718018463.793481234 ◽

2013 ◽

Author(s):

Bruce Brockstein ◽

Nicholas Campbell

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Randomised Trial ◽

Open Label ◽

Phase 3 ◽

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

The Lancet ◽

10.1016/s0140-6736(19)32591-7 ◽

2019 ◽

Vol 394 (10212) ◽

pp. 1915-1928 ◽

Cited By ~ 230

Author(s):

Barbara Burtness ◽

Kevin J Harrington ◽

Richard Greil ◽

Denis Soulières ◽

Makoto Tahara ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Open Label ◽

Phase 3 ◽

Faculty Opinions recommendation of Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.736682352.793578124 ◽

2020 ◽

Author(s):

Jaffer Ajani

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Squamous Cell ◽

Oesophageal Squamous Cell Carcinoma ◽

Open Label ◽

Phase 3 ◽

Abstract CT285: KEYNOTE-689: A phase 3 study of neoadjuvant and adjuvant pembrolizumab plus standard of care (SOC) in locally advanced (LA) head and neck squamous cell carcinoma (HNSCC)

10.1158/1538-7445.am2020-ct285 ◽

2020 ◽

Author(s):

Nancy Y. Lee ◽

Ravindra Uppaluri ◽

William Westra ◽

Ezra E. Cohen ◽

Robert I. Haddad ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Locally Advanced ◽

Standard Of Care ◽

Phase 3

A Phase I/II, Open-Label, Dose Escalation Followed by Single-Arm Expansion to Assess the Safety and Efficacy of NT219 in Combination with Cetuximab in Patients with Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC)

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2019.11.144 ◽

2020 ◽

Vol 106 (5) ◽

pp. 1182-1183

Author(s):

O. Ronen ◽

M. Shickler ◽

H. Reuveni ◽

I. Israel ◽

I. Haviv ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Phase I ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Dose Escalation ◽

Open Label ◽

Safety And Efficacy ◽

Label Dose